Patents by Inventor Pandiaraju Subramanian

Pandiaraju Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20230219926
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 13, 2023
    Inventors: Rima AL-AWAR, Carlos Armando ZEPEDA-VELAZQUEZ, Gennady PODA, Methvin ISAAC, David UEHLING, Brian WILSON, Babu JOSEPH, Yong LIU, Pandiaraju SUBRAMANIAN, Ahmed MAMAI, Michael PRAKESCH, Julia Katheleen STILLE
  • Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
    Patent number: 11518764
    Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: December 6, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 11319299
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 3, 2022
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille
  • Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
    Patent number: 11242351
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 8, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 11174250
    Abstract: The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 16, 2021
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai
  • TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20210053978
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: February 25, 2021
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20200385371
    Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: September 6, 2018
    Publication date: December 10, 2020
    Applicant: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Methvin Isaac, Joseph Babu, Yong Liu, Ahmed Mamai, Gennady Poda, Pandiaraju Subramanian, David Uehling, Brian Wilson, Carlos Armando Zepeda-Velazquez
  • INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20200331921
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: February 6, 2019
    Publication date: October 22, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20190119264
    Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 25, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20190112290
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 18, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille